The U.S. Food and Drug Administration granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.

Emergent BioSolutions’ Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19 showed that the addition of the treatment to Gilead Sciences’ remdesivir did not provide clinical benefit compared to standard of care plus placebo in hospitalized adult COVID-19 patients with symptoms for less than 12 days.

The CoVIg-19 Plasma Alliance was founded to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19.

New York will launch a clinical trial using blood plasma from patients who have recovered from COVID-19, the disease caused by the novel coronavirus.

Japanese drug manufacturer Takeda Pharmaceutical indicated that the company is attempting to develop a drug based on the blood of patients who recovered from COVID-19.